Targeted nanoparticles destroy tumor cells by triggering cuproptosis

A promising cancer treatment strategy called cuproptosis, which uses copper-dependent cell death to eliminate tumor cells, faces a major challenge: many approaches require adding external copper, potentially increasing toxicity beyond the tumor. A new study published in Biomedical Analysis introduces a targeted nanoparticle system that overcomes this limitation by using cancer cells' own copper resources to activate this form of cell death.

The core of this new system is a biocompatible nanoparticle made from PLGA-PEG, a polymer widely recognized for its safety and degradability. To ensure the nanoparticle reaches its destination, the researchers decorated its surface with a tumor-penetrating peptide called iRGD. This peptide acts like a navigation system, guiding the nanoparticle to bind specifically to tumor cells. The nanoparticle carries a potent payload: N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN), a chemical agent that chelates, or binds to, metal ions like copper.

Designing a precision delivery system

The research team meticulously prepared and characterized the final formulation, named TPEN@1%-iPPN. The nanoparticles were found to be uniform in size, measuring approximately 80 nanometers in diameter, an ideal size for accumulating in tumor tissue. Extensive stability tests confirmed that the nanoparticles remained intact under conditions mimicking the human bloodstream, including upon dilution and in the presence of serum proteins. This stability is essential for ensuring the payload reaches the tumor before degrading. The formulation also demonstrated a sustained-release profile, gradually releasing its TPEN cargo over 72 hours, which could help maintain a consistent therapeutic effect within the tumor microenvironment.

Homing in on cancer cells

The effectiveness of the iRGD targeting peptide was a central focus of the investigation. In laboratory experiments using 4T1 breast cancer cells, the iRGD-modified nanoparticles showed significantly enhanced cellular uptake compared to their non-targeted counterparts. Fluorescence microscopy and flow cytometry analyses confirmed that the targeted nanoparticles were internalized by cancer cells far more efficiently. The researchers determined that a 1% modification with the iRGD peptide provided the optimal balance of targeting efficacy and nanoparticle stability, achieving maximum cellular entry without compromising the formulation.

Selective toxicity: A double-edged sword for tumors

The ultimate test was whether the nanoparticles could kill cancer cells without harming normal cells. Cytotoxicity assays revealed that the targeted TPEN@1%-iPPN was significantly more lethal to 4T1 breast cancer cells than the non-targeted version. Most importantly, the nanoparticle formulation showed much lower toxicity to normal human endothelial cells (HUVECs) compared to free, untargeted TPEN. This demonstrates a high degree of tumor-selective cytotoxicity, concentrating the drug's lethal effect where it is needed most while protecting healthy tissue. This selectivity is a key advantage that could lead to a wider therapeutic window in future applications.

This preclinical work provides a robust experimental foundation for a new class of cancer nanomedicines that exploit the unique metabolic properties of tumors. By designing a delivery system that is stable, targeted, and capable of activating cuproptosis using endogenous copper, the authors have outlined a promising strategy for developing more precise and effective cancer treatments. This approach avoids the risks of systemic metal administration and offers a new way to think about leveraging a tumor's internal environment for therapeutic gain.

Our approach leverages the high copper levels already present in tumors, using a targeted nanoparticle to deliver a chelator that essentially turns the cancer cell's own biology against itself. This strategy of mobilizing endogenous copper offers a promising path to enhance selectivity and reduce the systemic side effects often seen with metal-based cancer therapies. We have provided a solid proof-of-concept at the cellular level, which we hope will inspire further research into cuproptosis-based nanomedicine."

Dr. Ying Chen, corresponding author of the study